Dual therapy can produce potent response in soft-tissue sarcoma

Share this article:

A combination of implanted immune system cells and external-beam radiation therapy (EBRT) safely induced antitumor immune responses in more than half of patients with high-risk soft-tissue sarcomas who had participated in a small trial.

Sarcomas are relatively rare forms of cancer, with about 10,000 new cases diagnosed in the United States each year, noted study coauthor Dmitry Gabrilovich, MD, PhD, senior member of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida. Approximately half of all patients with high-grade soft-tissue sarcomas develop distant metastasis.

“Unfortunately, conventional therapy for large, high-grade tumors is frequently systematically ineffective, making this a very deadly problem,” explained Gabrilovich in a statement issued by the Moffitt Center to announce the study results, which were published in International Journal of Radiation Oncology, Biology, Physics (2012;82[1]:924-932).

Gabrilovich and team combined administration of dendritic cells and EBRT in 17 patients with large (larger than 5 cm), high-grade soft-tissue sarcomas. Dendritic cells process antigen material and present it to other immune cells, making administration of dendritic cells a promising method for producing an immune response. Because previous research had shown preoperative radiotherapy and surgery to be an effective treatment for high-risk soft-tissue sarcomas, the investigators hypothesized that dendritic-cell implants combined with EBRT could each enhance the effectiveness of the other. 

Although none of the patients had experienced tumor-specific immune responses before undergoing dendritic cell/EBRT treatment, 9 patients (52.9%) developed such responses following treatment. The responses lasted from 11 to 42 weeks, with 12 of the 17 patients (70.6%) remaining progression-free after 1 year.

Gabrilovich and colleagues described the combination therapy as well-tolerated, and concluded that because a strong antitumor response was produced with no adverse side effects, larger trials involving more patients are warranted.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.